

# Rebecca Brown

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3635765/publications.pdf>

Version: 2024-02-01

70  
papers

3,042  
citations

159525

30  
h-index

168321

53  
g-index

70  
all docs

70  
docs citations

70  
times ranked

3283  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4500-4511.	1.8	323
2	Artificial Sweeteners: A systematic review of metabolic effects in youth. <i>Pediatric Obesity</i> , 2010, 5, 305-312.	3.2	178
3	Low-calorie sweetener consumption is increasing in the United States. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 640-646.	2.2	173
4	Ingestion of Diet Soda Before a Glucose Load Augments Glucagon-Like Peptide-1 Secretion. <i>Diabetes Care</i> , 2009, 32, 2184-2186.	4.3	141
5	The liver diseases of lipodystrophy: The long-term effect of leptin treatment. <i>Journal of Hepatology</i> , 2013, 59, 131-137.	1.8	138
6	Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8901-8906.	3.3	125
7	Partial and Generalized Lipodystrophy: Comparison of Baseline Characteristics and Response to Metreleptin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1802-1810.	1.8	124
8	Cushing Syndrome in the McCune-Albright Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1508-1515.	1.8	113
9	Non-Nutritive Sweeteners and their Role in the Gastrointestinal Tract. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2597-2605.	1.8	104
10	Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. <i>Pediatric Diabetes</i> , 2008, 9, 14-22.	1.2	88
11	Effects of Diet Soda on Gut Hormones in Youths With Diabetes. <i>Diabetes Care</i> , 2012, 35, 959-964.	4.3	85
12	The Clinical Approach to the Detection of Lipodystrophy an Aace Consensus Statement. <i>Endocrine Practice</i> , 2013, 19, 107-116.	1.1	83
13	Too Much Glucagon, Too Little Insulin. <i>Diabetes Care</i> , 2008, 31, 1403-1404.	4.3	82
14	Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. <i>Endocrine</i> , 2018, 60, 479-489.	1.1	79
15	Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy. <i>Journal of Clinical Investigation</i> , 2018, 128, 3504-3516.	3.9	74
16	Hormonal responses to non-nutritive sweeteners in water and diet soda. <i>Nutrition and Metabolism</i> , 2016, 13, 71.	1.3	68
17	Artificial Sweetener Use Among Children: Epidemiology, Recommendations, Metabolic Outcomes, and Future Directions. <i>Pediatric Clinics of North America</i> , 2011, 58, 1467-1480.	0.9	63
18	Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. <i>Endocrine</i> , 2019, 64, 500-511.	1.1	58

#	ARTICLE	IF	CITATIONS
19	Contribution of Adipose-Derived Factor D/Adipsin to Complement Alternative Pathway Activation: Lessons from Lipodystrophy. <i>Journal of Immunology</i> , 2018, 200, 2786-2797.	0.4	52
20	Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 59-68.	1.3	51
21	Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. <i>Clinical Endocrinology</i> , 2016, 85, 137-149.	1.2	44
22	Genetics of Lipodystrophy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, 539-554.	1.2	44
23	Effects of Metreleptin in Pediatric Patients With Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1511-1519.	1.8	42
24	Leptin Does Not Mediate Hypertension Associated With Human Obesity. <i>Cell</i> , 2015, 162, 465-466.	13.5	39
25	Clinical Features and Management of Non-HIV-Related Lipodystrophy in Children: A Systematic Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 363-374.	1.8	39
26	The Use of Low-Calorie Sweeteners by Children: Implications for Weight Management. <i>Journal of Nutrition</i> , 2012, 142, 1155S-1162S.	1.3	37
27	Bone Mineral Content in Patients With Congenital Generalized Lipodystrophy Is Unaffected by Metreleptin Replacement Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1493-E1500.	1.8	36
28	Metreleptin Improves Blood Glucose in Patients With Insulin Receptor Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1749-E1756.	1.8	35
29	Leptin decreases de novo lipogenesis in patients with lipodystrophy. <i>JCI Insight</i> , 2020, 5, .	2.3	35
30	Free fatty acid processing diverges in human pathologic insulin resistance conditions. <i>Journal of Clinical Investigation</i> , 2020, 130, 3592-3602.	3.9	35
31	Lymphoma in acquired generalized lipodystrophy. <i>Leukemia and Lymphoma</i> , 2016, 57, 45-50.	0.6	31
32	Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5120-5135.	1.8	29
33	Lipid Regulation in Lipodystrophy Versus the Obesity-Associated Metabolic Syndrome: The Dissociation of HDL-C and Triglycerides. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1676-E1680.	1.8	28
34	Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study. <i>Diabetes Care</i> , 2018, 41, 2353-2360.	4.3	28
35	Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARC vs LMNA Pathogenic Variants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3068-3076.	1.8	26
36	Advanced Lipoprotein Analysis Shows Atherogenic Lipid Profile That Improves After Metreleptin in Patients with Lipodystrophy. <i>Journal of the Endocrine Society</i> , 2019, 3, 1503-1517.	0.1	21

#	ARTICLE	IF	CITATIONS
37	Effects of Leptin Replacement Therapy on Pancreatic $\beta$ -Cell Function in Patients With Lipodystrophy. <i>Diabetes Care</i> , 2014, 37, 1101-1107.	4.3	19
38	Effects of Metreleptin on Patient Outcomes and Quality of Life in Generalized and Partial Lipodystrophy. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab019.	0.1	19
39	Consequences of Stopping and Restarting Leptin in an Adolescent with Lipodystrophy. <i>Hormone Research in Paediatrics</i> , 2012, 78, 320-325.	0.8	18
40	Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy. <i>Journal of Clinical Lipidology</i> , 2017, 11, 543-550.	0.6	18
41	Type B Insulin Resistance Masquerading As Ovarian Hyperthecosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 102, jc.2016-3674.	1.8	17
42	Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2367-2383.	1.8	16
43	Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients. <i>Endocrinology</i> , 2016, 157, 1421-1429.	1.4	15
44	Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2953-e2967.	1.8	13
45	Clinical trials in youth with type 2 diabetes. <i>Pediatric Diabetes</i> , 2011, 12, 50-57.	1.2	11
46	Thyroid Hormone Effects on Glucose Disposal in Patients With Insulin Receptor Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e158-e171.	1.8	11
47	Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2132-2141.	1.8	11
48	Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1790-1797.	1.8	10
49	Effects of Metreleptin on Proteinuria in Patients With Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4169-4177.	1.8	10
50	Thyroid Abnormalities in Patients With Extreme Insulin Resistance Syndromes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2216-2228.	1.8	10
51	Metabolomic Analysis of the Effects of Leptin Replacement Therapy in Patients with Lipodystrophy. <i>Journal of the Endocrine Society</i> , 2020, 4, bvz022.	0.1	10
52	Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4163-e4178.	1.8	9
53	Management of Diabetic Ketoacidosis in Severe Insulin Resistance. <i>Diabetes Care</i> , 2016, 39, e116-e118.	4.3	8
54	Complement Factor D (adipsin) Levels Are Elevated in Acquired Partial Lipodystrophy (Barraquerâ€™Simons syndrome). <i>International Journal of Molecular Sciences</i> , 2021, 22, 6608.	1.8	7

#	ARTICLE	IF	CITATIONS
55	Impaired Glucose Metabolism, Anti-Diabetes Medications, and Risk of Thyroid Cancer. <i>Cancers</i> , 2022, 14, 555.	1.7	7
56	Excess 11-Oxygenated Androgens in Women With Severe Insulin Resistance Are Mediated by Adrenal Insulin Receptor Signaling. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2626-2635.	1.8	7
57	Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use. <i>Current Medical Research and Opinion</i> , 2021, 37, 1881-1889.	0.9	6
58	Apolipoprotein CIII and Angiotensin-like Protein 8 are Elevated in Lipodystrophy and Decrease after Metreleptin. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa191.	0.1	6
59	Energy expenditure due to gluconeogenesis in pathological conditions of insulin resistance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E795-E801.	1.8	6
60	Visceral fat does not contribute to metabolic disease in lipodystrophy. <i>Obesity Science and Practice</i> , 2019, 5, 75-82.	1.0	5
61	Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4327-e4339.	1.8	5
62	Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1739-e1751.	1.8	5
63	Long-Term Effects of Metreleptin in Rabson-Mendenhall Syndrome on Glycemia, Growth, and Kidney Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1032-e1046.	1.8	5
64	Type 1 and Type 2 Diabetes in Five Race and Ethnic Populations: the SEARCH for Diabetes in Youth Study. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 175-177.	0.8	2
65	Effect of Leptin Replacement Therapy (LRT) on Survival and Disease Progression in Generalized and Partial Lipodystrophy (GL, PL). <i>Diabetes</i> , 2018, 67, .	0.3	2
66	Patient Quality of Life and Benefits of Leptin Replacement Therapy (LRT) in Generalized and Partial Lipodystrophy (GL, PL). <i>Diabetes</i> , 2018, 67, .	0.3	2
67	Other Antibodies Resulting in Diabetes Mellitus: Type B Insulin Resistance and Insulin Autoimmune Syndrome. <i>AACE Clinical Case Reports</i> , 2016, 2, e274-e275.	0.4	1
68	Finding a sweet spot for leptin. <i>Med</i> , 2021, 2, 794-796.	2.2	0
69	Rare case of rectosigmoid stricture causing transverse colon volvulus. <i>BMJ Case Reports</i> , 2021, 14, .	0.2	0
70	Clinical Effects of Sodium-Glucose Transporter Type 2 Inhibitors in Patients With Partial Lipodystrophy. <i>Endocrine Practice</i> , 2022, , .	1.1	0